败血症药物市场规模、份额和成长分析（按药物类别、病原体类型、治疗类型、给药途径、最终用户和地区划分）－2026-2033年产业预测

预计到 2024 年，全球败血症药物市场规模将达到 72.6 亿美元，到 2025 年将达到 74.3 亿美元，到 2033 年将达到 89.1 亿美元，预测期（2026-2033 年）的复合年增长率为 2.3%。

全球败血症治疗市场正经历强劲成长，主要受加护病房(ICU) 收治人数不断上升（尤其是在老龄化人口中）以及抗药性感染疾病日益增多（导致传统抗生素疗效降低）的推动。医院对免疫标靶治疗疗法和体外疗法的巨额投资，推动了对速效非抗生素疗法的需求。同时，政府支持和创业投资对医疗创新的投入也进一步增强了这一成长动能。新进入市场的企业正在开发先进的血液净化设备和免疫标靶治疗，以便在重症监护环境中进行快速介入。然而，市场仍面临诸多挑战，包括高昂的研发成本、漫长的监管审批流程、对败血症的认知不足、诊断延迟、医院采购流程复杂以及低收入地区医疗基础设施匮乏等，这些都可能阻碍市场扩张。

全球脓毒症药物市场驱动因素

全球败血症治疗市场的发展动力源自于应对败血症的迫切需求，败血症是全球医院死亡的主要原因之一。随着医疗系统面临加加护病房(ICU) 收治人数不断增加、人口老化以及抗生素抗药性感染疾病等挑战，亟需更有效的治疗方案。医院被迫加强对这项严重疾病的应对，这需要开发超越传统抗生素治疗的创新治疗方法和医疗设备。这种情况凸显了推动脓毒症管理解决方案的重要性，以改善患者预后并减轻这项严峻医疗挑战带来的负担。

限制全球脓毒症药物市场的因素

全球败血症治疗市场面临许多挑战，主要原因是新治疗方法核准成本高且流程漫长。临床试验需要严格的安全通讯协定，并招募大规模加护病房患者，这阻碍了小型公司进入市场，也抑制了整体成长。此外，鑑于这些治疗方法会与脆弱的免疫系统相互作用，人们越来越担心其安全性。监管要求增加了对大量数据和严格监督的需求，进一步复杂化了核准流程，并增加了该领域潜在开发人员面临的障碍。

全球脓毒症治疗市场趋势

全球败血症治疗市场正经历着向创新治疗方案的重大转变，这主要受败血症发病率上升和医疗专业人员认知度提高的推动。这一趋势的特点是研发活动激增，包括针对败血症的先进生物製药、免疫疗法和抗生素的推出。此外，数位健康科技和个人化医疗的融合正在改善患者管理和治疗效果。值得注意的是，该市场也高度重视製药公司与研究机构之间的策略合作，以加速药物研发。随着全球医疗系统将脓毒症管理列为优先事项，对治疗药物的投资至关重要。

目录

介绍

• 调查目标
• 市场定义和范围

调查方法

• 调查过程
• 二手资料和一手资料方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争格局概述

市场动态与展望

• 总体经济指标
• 驱动因素和机会
• 限制与挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

关键市场考察

• 关键成功因素
• 影响市场的因素
• 关键投资机会
• 生态系测绘
• 市场吸引力指数（2025）
• PESTEL 分析
• 价值链分析
• 定价分析
• 案例研究
• 监管环境
• 技术评估
• 技术评估
• 监管环境

全球脓毒症药物市场规模（按药物类别和复合年增长率划分）（2026-2033 年）

• 抗生素
• 抗真菌药物
• 皮质类固醇
• 免疫调节剂
• 血管加压药
• 止痛药和镇静剂
• 抗凝血剂

全球败血症药物市场规模（按病原体类型和复合年增长率划分）（2026-2033 年）

• 细菌性败血症
• 霉菌性败血症
• 病毒性败血症

全球败血症治疗市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

• 液体復苏
• 血液净化技术
• 症状支持治疗
• 标靶免疫疗法

全球败血症药物市场规模（依给药途径及复合年增长率划分）（2026-2033 年）

• 静脉注射
• 口服
• 其他的

全球脓毒症治疗市场规模（按最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 门诊手术中心
• 诊所
• 研究和学术机构

全球败血症治疗市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline plc
• Novartis AG
• Merck & Co., Inc.
• Johnson & Johnson
• AbbVie Inc.
• Eli Lilly and Company
• AstraZeneca plc
• Bayer AG
• Baxter International Inc.
• Becton, Dickinson and Company（BD）
• Thermo Fisher Scientific Inc.
• CSL Behring
• Grifols SA
• BioMerieux SA
• Bio-Rad Laboratories
• Shionogi & Co., Ltd.
• Sandoz（Novartis division）
• Takeda Pharmaceutical Company Limited

结论与建议

Global Sepsis Therapeutics Market size was valued at USD 7.26 Billion in 2024 and is poised to grow from USD 7.43 Billion in 2025 to USD 8.91 Billion by 2033, growing at a CAGR of 2.3% during the forecast period (2026-2033).

The global sepsis therapeutics market is experiencing robust growth driven by a rising number of ICU admissions, particularly among the aging population, and an increase in drug-resistant infections that diminish the efficacy of traditional antibiotics. The demand for rapid-acting non-antibiotic therapies is escalating, spurred by significant hospital investments in immune-targeted and extracorporeal treatments, while governmental support and venture capital investment in medtech innovations enhance this momentum. New players in the market are developing advanced blood purification devices and immune-targeted therapies to facilitate quicker intervention in critical care settings. Nonetheless, challenges remain, including high development costs, slow regulatory processes, limited awareness of sepsis, late diagnoses, complex procurement dynamics in hospitals, and inadequate healthcare infrastructure in low-income regions that may impede market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Sepsis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Sepsis Therapeutics Market Segments Analysis

Global Sepsis Therapeutics Market is segmented by Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Antibiotics, Antifungals, Corticosteroids, Immunomodulators, Vasopressors, Analgesics and Sedatives and Anticoagulants. Based on Pathogen Type, the market is segmented into Bacterial Sepsis, Fungal Sepsis and Viral Sepsis. Based on Treatment Type, the market is segmented into Fluid Resuscitation, Blood Purification Techniques, Symptomatic and Supportive Care and Targeted Immunotherapy. Based on Route of Administration, the market is segmented into Intravenous, Oral and Others. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Clinics and Research and Academic Institutes. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Sepsis Therapeutics Market

The global sepsis therapeutics market is driven by the urgent need to address sepsis, a major contributor to hospital mortality rates internationally. As health systems grapple with increasing ICU admissions, an aging population, and the challenge of antibiotic-resistant infections, there is a pressing demand for more effective treatment options. Hospitals are seeking to enhance their response to this critical condition, necessitating the development of innovative therapies and medical devices that go beyond conventional antibiotic treatments. This dynamic landscape underscores the importance of advancing sepsis management solutions to improve patient outcomes and reduce the burden of this severe healthcare challenge.

Restraints in the Global Sepsis Therapeutics Market

The Global Sepsis Therapeutics market faces significant challenges due to the high costs and lengthy processes associated with securing approval for new treatments. Clinical trials demand recruitment of substantial cohorts of intensive care unit patients alongside stringent safety protocols, which can deter smaller companies from entering the market and impede overall growth. Additionally, there is heightened concern regarding the safety of these treatments, given their interaction with vulnerable immune systems. In response to regulatory requirements, the necessity for extensive data and oversight has increased, further complicating the approval process and adding to the obstacles faced by potential developers in this field.

Market Trends of the Global Sepsis Therapeutics Market

The Global Sepsis Therapeutics market is witnessing a significant shift toward innovative treatment solutions driven by rising incidences of sepsis and increasing awareness among healthcare professionals. This trend is marked by a surge in research and development efforts, leading to the introduction of advanced biologics, immunotherapies, and antibiotics specifically targeting sepsis. Furthermore, the integration of digital health technologies and personalized medicine is enhancing patient management and outcomes. The market is also experiencing a strategic focus on partnerships and collaborations between pharmaceutical companies and research institutions to accelerate drug development. As healthcare systems globally prioritize sepsis management, investment in therapeutics is becoming paramount.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment
• Technology Assessment
• Regulatory Landscape

Global Sepsis Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Antibiotics
• Antifungals
• Corticosteroids
• Immunomodulators
• Vasopressors
• Analgesics and Sedatives
• Anticoagulants

Global Sepsis Therapeutics Market Size by Pathogen Type & CAGR (2026-2033)

• Market Overview
• Bacterial Sepsis
• Fungal Sepsis
• Viral Sepsis

Global Sepsis Therapeutics Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Fluid Resuscitation
• Blood Purification Techniques
• Symptomatic and Supportive Care
• Targeted Immunotherapy

Global Sepsis Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Oral
• Others

Global Sepsis Therapeutics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Research and Academic Institutes

Global Sepsis Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • US
  • Canada
• Europe (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Pathogen Type, Treatment Type, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shionogi & Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz (Novartis division)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations